Endogenous thrombopoietin (eTPO) regulates platelet production by increasing the number,
ploidy, and maturation rate of bone marrow megakaryocytes. Early attempts to treat
thrombocytopenia by the administration of recombinant TPO were successful but were
complicated by the development of antibodies to one of the recombinant proteins. Two new
TPO mimetics have recently been approved by the US Food and Drug Administration (FDA)
for the treatment of immune thrombocytopenia (ITP). Romiplostim is a peptide TPO mimetic …